MoonLake Immunotherapeutics
MLTX
$17.80
-$0.20-1.11%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -74.51% | -36.89% | -97.02% | -127.56% | -192.14% |
| Total Depreciation and Amortization | 123.54% | 106.32% | 112.25% | 116.96% | 15.24% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 668.13% | 329.25% | 103.11% | -16.01% | 44.52% |
| Change in Net Operating Assets | -2,938.48% | 100.15% | 158.72% | 77.65% | 87.03% |
| Cash from Operations | -73.80% | -21.29% | -76.23% | -95.52% | -155.15% |
| Capital Expenditure | -- | 100.00% | 100.00% | -- | 83.49% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -99.83% | 79.67% | 51.34% | 200.58% | 296.84% |
| Cash from Investing | -99.83% | 79.70% | 51.68% | 200.58% | 295.27% |
| Total Debt Issued | -66.49% | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 6,077.00% | 47,843.71% | 427.47% | -- | -99.81% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -58.09% | 47,843.71% | 162.30% | -- | 43.44% |
| Foreign Exchange rate Adjustments | -448.86% | -78.54% | 12.31% | 8,282.35% | -291.30% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -139.53% | 91.69% | 34.05% | 130.36% | 1,153.30% |